SciSparc: MitoCareX Appointed Professor Nir Peled, Seasoned Oncologist, to its Scientific Advisory Board

Rhea-AI Summary

SciSparc (Nasdaq: SPRC) announced that MitoCareX Bio , its joint venture focusing on cancer drug discovery, has appointed Professor Nir Peled to its scientific advisory board. Prof. Peled, Director of Oncology at Shaare Zedek Medical Center and chair of the IASLC's Global Multidisciplinary Practice Standards Committee, brings extensive expertise in thoracic oncology. His research focuses on personalized targeted therapy, immunotherapy, and biomarker development for lung cancer.

This appointment follows MitoCareX's recent validation of its target SLC25 carrier protein in Non-Small Cell Lung Cancer cells. The company has identified potential anti-cancer treatments using its proprietary MITOLINE™ algorithm and advanced drug discovery platform.

Positive

• Appointment of a distinguished oncology expert to the scientific advisory board
• Recent validation of target SLC25 carrier protein in NSCLC cells
• Identification of potential anti-cancer treatments using proprietary technology

Negative

• None.

Professor Peled is the Director of the Oncology Department at the Shaare Zedek Medical Center, Jerusalem, Israel, and the head of the Global Multidisciplinary Practice Standards Committee (GMPSC) of the IASLC

TEL AVIV, Israel, Aug. 22, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (the "Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announced that MitoCareX Bio Ltd. ("MitoCareX"), the Company’s venture with Dr. Alon Silberman that focuses on drug discovery and development of therapeutics for cancer and other life-threatening conditions by targeting the mitochondrial SLC25 protein family, has appointed Professor Nir Peled as a member of its scientific advisory board.

Professor Peled is a distinguished expert in thoracic oncology, holding board certifications in internal medicine, pulmonology, and medical oncology. His extensive contributions to the field are well-recognized, having served as a board member of the International Association for the Study of Lung Cancer (IASLC) and currently the chair of the Global Multidisciplinary Practice Standards Committee (GMPSC), as well as past Chair of the IASLC's Screening & Early Detection Committee. Additionally, he recently concluded his term as the Chair of the Thoracic Cancer Assembly of the European Thoracic Society.

With a research portfolio that spans translational and clinical aspects of lung cancer, Professor Peled's work is focused on personalized targeted therapy, immunotherapy, cancer evolution, biomarker development, and the early detection of lung cancer. His scholarly output includes over 250 peer-reviewed publications, encompassing key guidelines on the early diagnosis of lung cancer, biomarker development, and the treatment of advanced disease. Professor Peled also serves on the editorial boards of numerous prestigious journals, including the Journal of Thoracic Oncology, further contributing to the advancement of lung cancer research and treatment.

Dr. Alon Silberman, Chief Executive Officer of MitoCareX, comment “We are proud to welcome Professor Nir Peled, a Key Opinion Leader oncologist with an impressive track record, to our team. We believe that his professional contributions will be significant as we continue to advance our company's cutting-edge technologies for discovering and developing innovative cancer treatments.”

As previously announced by the Company on July 22, 2024, MitoCareX validated the significant involvement of its target SLC25 carrier protein, using Non-Small Cell Lung Cancer (NSCLC) cells with diverse genetic backgrounds. MitoCareX demonstrated the discovery by utilizing genetic manipulations and 3D spheroid systems, mimicking the main features of human solid tumors. Previously, MitoCareX had virtually screened millions of small molecules by using its computationally advanced drug discovery platform, which includes its proprietary MITOLINE™ algorithm. Following the successful virtual screening campaign, MitoCareX identified several small molecules that could potentially be used for anti-cancer treatments.

About SciSparc Ltd. (Nasdaq: SPRC):

SciSparc Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists. SciSparc’s focus is on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. With this focus, the Company is currently engaged in the following drug development programs based on THC and/or non-psychoactive CBD: SCI-110 for the treatment of Tourette Syndrome, for the treatment of Alzheimer's disease and agitation; SCI-160 for the treatment of pain; and SCI-210 for the treatment of ASD and status epilepticus. The Company also owns a controlling interest in a subsidiary whose business focuses on the sale of hemp seeds’ oil-based products on Amazon Marketplace.

Forward-Looking Statements:

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. For example, SciSparc is using forward-looking statements when it discusses MitoCareX’s belief that Professor Peled’s professional contributions will be significant. Historical results of scientific research and clinical and preclinical trials do not guarantee that the conclusions of future research or trials will suggest identical or even similar conclusions. Because such statements deal with future events and are based on SciSparc's current expectations, they are subject to various risks and uncertainties and actual results, performance or achievements of SciSparc could differ materially from those described in or implied by the statements in this press release. The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed under the heading "Risk Factors" in SciSparc's Annual Report on Form 20-F filed with the SEC on April 1, 2024, and in subsequent filings with the U.S. Securities and Exchange Commission. Except as otherwise required by law, SciSparc disclaims any intention or obligation to update or revise any forward-looking statements, which speak only as of the date they were made, whether as a result of new information, future events or circumstances or otherwise.

Investor Contact:
IR@scisparc.com
Tel: +972-3-6167055

FAQ

Who is Professor Nir Peled and why was he appointed to MitoCareX's scientific advisory board?

Professor Nir Peled is a distinguished expert in thoracic oncology, appointed to MitoCareX's scientific advisory board due to his extensive experience and contributions to lung cancer research. He is the Director of Oncology at Shaare Zedek Medical Center and chair of the IASLC's Global Multidisciplinary Practice Standards Committee.

What recent progress has MitoCareX made in cancer drug discovery?

MitoCareX recently validated the involvement of its target SLC25 carrier protein in Non-Small Cell Lung Cancer cells. The company has also identified potential anti-cancer treatments using its proprietary MITOLINE™ algorithm and advanced drug discovery platform.

How might Professor Peled's appointment impact SciSparc's (SPRC) drug development efforts?

Professor Peled's expertise in thoracic oncology and personalized targeted therapy could significantly contribute to SciSparc's (SPRC) drug development efforts through MitoCareX. His knowledge may help advance the company's cancer treatment research and potentially improve their drug discovery process.

What is the focus of MitoCareX Bio , SciSparc's (SPRC) joint venture?

MitoCareX Bio , SciSparc's (SPRC) joint venture, focuses on drug discovery and development of therapeutics for cancer and other life-threatening conditions. Their approach targets the mitochondrial SLC25 protein family using advanced computational drug discovery methods.